Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?
OBJECTIVE
To compare a restrictive red blood cell transfusion strategy with a more liberal strategy in volume-resuscitated critically ill patients with cardiovascular disease.


METHODS
Twenty-two academic and three community critical care units across Canada.


METHODS
Randomized controlled clinical trial.


METHODS
Three hundred fifty-seven critically ill patients with cardiovascular diseases from the Transfusion Requirements in Critical Care trial who had a hemoglobin concentration of <90 g/L within 72 hrs of admission to the intensive care unit.


METHODS
Patients were randomized to a restrictive strategy to receive allogeneic red blood cell transfusions at a hemoglobin concentration of 70 g/L (and maintained between 70 and 90 g/L) or a liberal strategy to receive red blood cells at 100 g/L (and maintained between 100 and 120 g/L).


RESULTS
Baseline characteristics in the restrictive (n = 160) and the liberal group (n = 197) were comparable, except for the use of cardiac and anesthetic drugs (p <.02). Average hemoglobin concentrations (85 +/- 6.2 vs. 103 +/- 6.7 g/L; p <.01) and red blood cell units transfused (2.4 +/- 4.1 vs. 5.2 +/- 5.0 red blood cell units; p <.01) were significantly lower in the restrictive compared with the liberal group. Overall, all mortality rates were similar in both study groups, including 30-day (23% vs. 23%; p = 1.00), 60-day, hospital, and intensive care unit rates. Changes in multiple organ dysfunction from baseline scores were significantly less in the restrictive transfusion group overall (0.2 +/- 4.2 vs. 1.3 +/- 4.4; p =.02). In the 257 patients with severe ischemic heart disease, there were no statistically significant differences in all survival measures, but this is the only subgroup where the restrictive group had lower but nonsignificant absolute survival rates compared with the patients in the liberal group.


CONCLUSIONS
A restrictive red blood cell transfusion strategy generally appears to be safe in most critically ill patients with cardiovascular disease, with the possible exception of patients with acute myocardial infarcts and unstable angina.
Hébert
P C
PC
Critical Care Programs, University of Ottawa, Ottawa, ON, Canada.
Yetisir
E
E
Martin
C
C
Blajchman
M A
MA
Wells
G
G
Marshall
J
J
Tweeddale
M
M
Pagliarello
G
G
Schweitzer
I
I
D018806:APACHE; D000368:Aged; D000740:Anemia / Q000150:complications* / Q000628:therapy*; D001803:Blood Transfusion / Q000379:methods / Q000706:statistics & numerical data*; D002318:Cardiovascular Diseases / Q000150:complications*; D002423:Cause of Death; D002985:Clinical Protocols / Q000592:standards; D015897:Comorbidity; D003422:Critical Care / Q000379:methods / Q000592:standards; D016638:Critical Illness / Q000401:mortality / Q000628:therapy*; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007902:Length of Stay / Q000706:statistics & numerical data; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000209:etiology / Q000401:mortality; D018579:Patient Selection; D016016:Proportional Hazards Models; D012449:Safety; D016019:Survival Analysis; D065227:Transfusion Reaction
D006454:Hemoglobins